ARGO-BLOCKCHAIN
Argo, the leading cryptocurrency miner based in the UK (LSE:ARB), is pleased to announce that it has entered into a securities purchase agreement for a private placement of its ordinary shares ("Ordinary Shares") to certain institutional investors for gross proceeds of GBP £22.4 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 28 million Ordinary Shares (the “Placement Shares”) at a purchase price of GBP £0.80 per Ordinary Share. The Private Placement is limited to those certain institutional investors that have already subscribed and this announcement should not be considered an offer or solicitation to purchase or subscribe for securities in the United States.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement.
The net proceeds of the Private Placement will be used by the Company for working capital and general corporate purposes, including the expansion of the Company’s mining capacity in Q1 and Q2 of 2021 through a purchase from two leading manufacturers. This new mining hardware expansion is expected to be installed in batches at Core Scientific’s facilities in the United States between February to June, and is scheduled to be fully operational by June 2021. This expansion will add approximately 610 petahash to the Company's installed computing power, bringing it to a total of 1,685 petahash or 1,68 Exahash by the end of Q2 2021.
Application will be made for the Placement Shares to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange. Admission and the closing of the Private Placement are expected to occur on or about 21 January 2021. The Placement Shares will rank pari passu with the existing Ordinary Shares of the Company.
Following Admission, the total number of Ordinary Shares in issue will be 355,828,456 and the total number of voting rights will therefore be 355,828,456. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Disclaimers:
FORWARD LOOKING STATEMENTS
This news release contains "forward-looking statements," which can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "estimate," "project," "continue" and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The information in this news release about future plans and objectives of the Company, including the expectation to complete the private placement and the expected expenditure of the proceeds of the private placement, are forward-looking information. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, market and other conditions, the principal risks and uncertainties listed in our risk factors set forth in our Annual Report and Financial Statements for the year ended December 31, 2019 and our Interim Report as of June 30, 2020.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent registration under U.S. federal and state securities laws or an applicable exemption from such U.S. registration requirements.
About Argo:
Argo Blockchain plc is a global leader in cryptocurrency mining with one of the largest and most efficient operations powered by clean energy. The Company is headquartered in London, UK and its shares are listed on the Main Market of the London Stock Exchange under the ticker: ARB.
See Argo's largest facility in Quebec:
https://youtu.be/LDWWaZ75Zbk
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE US
View source version on businesswire.com: https://www.businesswire.com/news/home/20210118005161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante Celebrates 18 Years of Carbon Management Innovation with Historic Milestones in 202530.10.2025 17:25:00 CET | Press release
Svante Technologies Inc. (Svante), a global leader in carbon capture and removal solutions, proudly marks its 18th anniversary this month, celebrating nearly two decades of pioneering industrial carbon management technology. This year has been one of the most transformative in Svante’s history, defined by bold innovation, strategic partnerships, and the commissioning of the world’s first commercial manufacturing facility for solid sorbent-based carbon capture and removal filters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030974500/en/ Founded in 2007 with a vision to revolutionize how the world manages carbon dioxide emissions, Svante has grown into a cornerstone of the global carbon management industry. In 2025, that vision took a monumental leap forward with the launch of the Redwood Facility in Burnaby, BC — a 141,000-square-foot Centre of Excellence for Carbon Capture and Removal. This first-of-its-kind manufactu
Ireland Unveils Seven New Halloween Experiences30.10.2025 15:00:00 CET | Press release
More celebrations than ever across the island of Ireland – the true Home of Halloween With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169
Staloral® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 14:56:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 14:00:00 CET | Press release
An Alliance to Combat Resistance: Debiopharm and NetTargets will collaborate to develop next-generation, dual-payload Antibody-Drug Conjugates (ADCs) designed to overcome acquired resistance mechanisms in difficult-to-treat cancers. AI-Powered Precision: The collaboration combines NetTargets' proprietary AI discovery platform—to identify synergistic drug pairings—with Debiopharm’s MLINK Duo technology for coordinated delivery of two distinct warheads on a single ADC. Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This allianc
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 14:00:00 CET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
